Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women

Hormone and Metabolic Research

Volumn 33, Issue 10, 2001, Pages 602-607

  Mertens, I ^a   Van der Planken, M ^a   Corthouts, B ^a   Wauters, M ^a   Peiffer, F ^a   De Leeuw, I ^a   Van Gaal, L ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Fibrinolysis; Obesity; Type 2 Diabetes; Visceral Adipose Tissue

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; FEMALE; FIBRINOLYSIS; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; THROMBOSIS;

ABDOMEN; ADIPOSE TISSUE; AGED; BODY MASS INDEX; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOLYSIS; HUMANS; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGRESSION ANALYSIS;

EID: 0034747975     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-17907     Document Type: Article

References (60)

1. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is ... or is it?
2. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study
3. Plasminogen activator inhibitor: A risk factor for myocardial infarction in diabetic patients
4. PAI-1, obesity, insulin resistance and risk of cardiovascular events
5. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
6. Involvement of the hemostatic system in the insulin resistance syndrome
7. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study
8. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
9. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries
10. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women
11. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome
12. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects
13. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects
14. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenic link between obesity and cardiovascular disease
15. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity
16. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
17. Expression of plasminogen activator inhibitor-1 in human adipose tissue: A role for TNF-α?
18. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β
19. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-α and lipopolysaccharide
20. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease
21. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level
22. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 Years of follow-up of the participants in the study of men born in 1913
23. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men
24. Visceral adiposity and risk of type 2 diabetes: A prospective study among Japanese Americans
25. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation
26. Assessment of fat-free mass using bioelectrical impedance measurements of the human body
27. Changes in fat-free mass during weight loss measured by bioelectrical impedance and by densitometry
28. Techniques for the measurement of visceral fat: A practical guide
29. Abnormal body fat distribution detected by computed tomography in diabetic men
30. Magnetic-resonance imaging used for determining fat distribution in obesity and diabetes
31. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography
32. Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction
33. Blood coagulation and fibrinolysis in obese NIDDM patients
34. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients
35. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus
36. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes
37. Hypercoagulability and high lipoprotein (a) levels in patients with type II diabetes mellitus
38. Plasminogen activator inhibitor-1 in nonobese subjects with non-insulin-dependent diabetes mellitus
39. Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity?
40. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men
41. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women
42. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women. Modulation by cross-sex hormone administration
43. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss
44. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: Stimulation by glucocorticoids and inhibition by catecholamines
45. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture
46. TNF-α and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes
47. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes
48. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue
49. Beta-adrenoceptor agonists and other cAMP elevating agents suppress PAI-1 production of human adipocytes in primary culture
50. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance
51. Relationship between plasma plasmiogen activator inhibitor 1 and insulin resistance
52. Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue
53. Hypertriglyceridemia and regulation of fibrinolytic activity
54. Augmentation of expression of plasminogen activator inhibitor type-1 in adipocytes and its potential role in acceleration of vasculopathy associated with obesity
55. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
56. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 gene during very low calorie diet in obese subjects
57. Release of PAI-1 by human preadipocytes and adipocytes independent of insulin and IGF-1
58. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose
59. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus
60. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients